Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Oramed Pharmaceuticals, Inc.

NEW YORK, Feb. 4, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (NasdaqCM: ORMP).  Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at [e-mail] or 212-697-6484.

The investigation concerns whether Oramed and certain of its officers and/or directors have violated federal securities laws.  On Monday, February 3, 2014, a report was published on TheStreet.com website questioning the integrity and robustness of the data presented by the Company regarding its Oral Insulin Pill, with the report calling such data "Completely Worthless". 

On this news, shares of Oramed fell $5.32 or 24.08% to close at $16.77.

If you are aware of any facts relating to this investigation, or purchased shares of Oramed you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [e-mail].  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[e-mail]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Copyright 2014 PR Newswire